| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Cell Biology (P.M., R.C.E., S.L.C.W.), Department of Pediatrics (K.C.C.), Howard Hughes Medical Institute (S.L.C.W.), Baylor College of Medicine, Houston Texas 77030
Type 1 diabetes mellitus is caused by a lack of insulin that results from the autoimmune destruction of the pancreatic ß-cells. Severe diabetes, if not controlled by periodic insulin injections, can lead to ketoacidosis and death. We have previously shown that sustained low level production of insulin in the liver of diabetic rats prevented their death from complications of diabetes. To test the hypothesis that there is a window of serum insulin concentrations that can prevent ketoacidosis without significant risk of hypoglycemia secondary to hyperinsulinemia, rats were infused with various doses of a recombinant retrovirus encoding an engineered rat preproinsulin-1 gene. The gene was engineered to allow processing into mature insulin by the protease furin. At the lower doses tested, fatal ketoacidosis was prevented, but the rats exhibited nonfasting hyperglycemia. At intermediate doses, which resulted in serum insulin concentrations of 1.6 mg/ml, the rats achieved near-normoglycemia and no serum ketones. These rats did not exhibit hypoglycemia even during a 24-h fast. At high virus doses, the animals achieved nonfasting normoglycemia but exhibited hypoglycemia during the fast. In conclusion, we have defined a therapeutic window of hepatic insulin expression that provides protection against ketoacidosis without significant risk of hypoglycemia. This window of sustained hepatic insulin expression might permit its development into a novel treatment modality for the prevention of ketoacidosis in patients with severe insulin-dependent diabetes mellitus.
This article has been cited by other articles:
 |
|
 |
|
  Y.-C. Lu, C. Sternini, E. Rozengurt, and E. Zhukova Release of Transgenic Human Insulin from Gastric G Cells: A Novel Approach for the Amelioration of Diabetes Endocrinology, June 1, 2005; 146(6): 2610 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Zhu, A. Abdo, J. F. Gesmonde, K. C. Zawalich, W. Zawalich, and P. S. Dannies Aggregation and Lack of Secretion of Most Newly Synthesized Proinsulin in Non-{beta}-Cell Lines Endocrinology, August 1, 2004; 145(8): 3840 - 3849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Suhara, Y. Sawa, N. Fukushima, K. Kagisaki, C. Yokoyama, T. Tanabe, S. Ohtake, and H. Matsuda Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats J. Thorac. Cardiovasc. Surg., May 1, 2002; 123(5): 855 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Riu, A. Mas, T. Ferre, A. Pujol, L. Gros, P. Otaegui, L. Montoliu, and F. Bosch Counteraction of Type 1 Diabetic Alterations by Engineering Skeletal Muscle to Produce Insulin: Insights From Transgenic Mice Diabetes, March 1, 2002; 51(3): 704 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Dong, J. Altomonte, N. Morral, M. Meseck, S. N. Thung, and S. L.C. Woo Basal Insulin Gene Expression Significantly Improves Conventional Insulin Therapy in Type 1 Diabetic Rats Diabetes, January 1, 2002; 51(1): 130 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Halban, S. E. Kahn, A. Lernmark, and C. J. Rhodes Gene and Cell-Replacement Therapy in the Treatment of Type 1 Diabetes: How High Must the Standards Be Set? Diabetes, October 1, 2001; 50(10): 2181 - 2191. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. K. Short, S. Okada, K. Yamauchi, and J. E. Pessin Adenovirus-mediated transfer of a modified human proinsulin gene reverses hyperglycemia in diabetic mice Am J Physiol Endocrinol Metab, November 1, 1998; 275(5): E748 - E756. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
